EMICIZUMAB DATA
Patient Management Topics
The Genentech resources below are patient-friendly summaries of data related to emicizumab and select management topics. These patient-friendly summaries include studies with the strongest and most relevant data and are provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.
Breakthrough Bleeds
HEMLIBRA and Treating Breakthrough Bleeds in Hemophilia A Without Inhibitors
Laboratory Tests
HEMLIBRA Effect
on Laboratory Monitoring Tests for Clotting
Surgeries and Procedures
HEMLIBRA and
Surgeries and Procedures
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
Breakthrough Bleeds
Untreated Bleeds in People With Hemophilia A in a Noninterventional Study and Intrapatient Comparison After Initiating Emicizumab in HAVEN 1-3
Callaghan MU, Asikanius E, Lehle M, et al. Res Pract Thromb Haemost 2022;6:e12782.
Factor VIII Use in the Treatment of Breakthrough Bleeds in Persons With Hemophilia A Without Inhibitors on Emicizumab Prophylaxis: The Phase III HAVEN 3 Study Experience
Callaghan M, Trzaskoma B, Ko R, et al. Presented at the Virtual HFA Scientific Meeting; August 24-29, 2020.
Laboratory Tests
Effects and Interferences of Emicizumab, a Humanized Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
Adamkewicz JI, Chen DC, Paz-Priel Il. Thromb Haemost. 2019;119:1084–1093.
Surgeries and Procedures
Surgical Outcomes in People With Hemophilia A Taking Emicizumab Prophylaxsis: Experience From the HAVEN 1-4 Studies
Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Blood Adv. 2022. doi: 10.1182/bloodadvances.2022007458.
Surgical Experience From Four Phase III Studies (HAVEN 1-4) of Emicizumab in Persons With Haemophilia A (PwHA) With or Without FVIII Inhibitors
Santagostino E, Oldenburg J, Chang T, et al. Presented at ISTH; July 6–10, 2019.
Surgical Experience From the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons With Hemophilia A With FVIII Inhibitors: Final Analysis
Castaman G, Windgya J, Alzahrani H, et al. Presented at ASH; December 11-14, 2021.